Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reena Philip

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2020
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast CancerPreeti Narayan, Tatiana M Prowell, Jennifer J Gao, et al.
JCO Precision Oncology|August 11, 2022
Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint InhibitorsDiana Merino Vega, Katherine K Nishimura, Névine Zariffa, et al.
Clinical Pharmacology and Therapeutics|February 5, 2020
Minimum Technical Data Elements for Liquid Biopsy Data Submitted to Public DatabasesPhillip G Febbo, Anne-Marie Martin, Howard I Scher, et al.
Nature Biotechnology|August 3, 2010
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive modelsLeming Shi, Gregory Campbell, Wendell D Jones, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2020
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast CancerPreeti Narayan, Tatiana M Prowell, Jennifer J Gao, et al.
JCO Precision Oncology|August 11, 2022
Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint InhibitorsDiana Merino Vega, Katherine K Nishimura, Névine Zariffa, et al.
Clinical Pharmacology and Therapeutics|February 5, 2020
Minimum Technical Data Elements for Liquid Biopsy Data Submitted to Public DatabasesPhillip G Febbo, Anne-Marie Martin, Howard I Scher, et al.
Nature Biotechnology|August 3, 2010
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive modelsLeming Shi, Gregory Campbell, Wendell D Jones, et al.
Pageof 6